A randomized, multicenter, double-blind placebo-controlled study in adults with MASLD showed that the DGAT1 inhibitor Pradigastat reduced liver fat content at 24 weeks compared to placebo, although diarrhea affected more than 50% of patients receiving the drug (NCT01811472). This evidence concerns the gene DGAT1 and metabolic dysfunction-associated steatotic liver disease.